2020 AACR: Multifunction lysoid virus BT-001 has strong activity on solid tumors
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Biotech companies BioInvent and Transgene today released preclinical data on the multifunction lysoid virus BT-001 for cancer treatment, demonstrating the broad therapeutic potential of BT-001 for solid tumors with anti-CTLA4 antibody coding lysome virusThis data will be presented at AACR 2020BT-001 is a multifunction lysooma virus developed by BioInvent and TransgeneIt is engineered to encode Treg depleted anti-CTLA4 antibodiesIt uses Transgene's vaccine-based Invir.IO ™ viral vector platform to deliver this powerful immunotherapy directly to tumor tissuelysome virus is invaded into tumor cells through cell surface molecules, so one of the effective strategies of lysome virus treatment is to modify the tumor virus with specific tumor virus, and then target those specific receptors that are over-expressed in tumor cells, invade the virus into tumor cells and exercise subsequent functionsThis preclinical data shows strong therapeutic effects, and in mice with multiple solid tumor models (CT26, EMT6, C38, and A20), BT-001 demonstrates the potential for single-drug cureIn combination with anti-PD-1 antibody therapy, the activity of BT-001 is further enhanced
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
